4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020687
PRESIDENT AND CEO sold 2,270 shares at $27.56 ($62,555)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · PRESIDENT AND CEO
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-07-31 | Sale : show line 1 in the form 10b5-1 | −2,270 | $27.56 | $62,555 | 1,061,255 | I |
| Open-market sales · 2,270 sh · avg $27.56 · $62,555 | ||||||
Loading xslF345X05/form4-08022024_110802.xml…